<DOC>
	<DOCNO>NCT00502112</DOCNO>
	<brief_summary>This study phase I , open-label , single-arm , dose escalation trial determine safety activity lenalidomide combine lintuzumab patient MDS . Small group 3-6 patient treat pre-specified dos lenalidomide lintuzumab receive 3-week cycle combination therapy .</brief_summary>
	<brief_title>A Phase I Study Lintuzumab Combined With Lenalidomide Patients With Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Disease confirmation MDS . 2 . Between 5 % 30 % blast bone marrow . 3 . Received treatment cytopenia within 2months 4 . ECOG ≤ 2 . 1 . Received prior therapy lenalidomide , gemtuzumab ozogamicin ( Mylotarg® ) . 2 . Received chemotherapy/radiotherapy within 4 week study registration . 3 . Received prior bone marrow transplant . 4 . 5q chromosomal deletion malignant cell .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Lintuzumab</keyword>
	<keyword>Antigens , CD33</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Preleukemia</keyword>
</DOC>